Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model


Arena Pharmaceuticals



) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.4%. By the end of trading, Arena Pharmaceuticals fell 19 cents (-2%) to $9.06 on light volume. Throughout the day, 6.6 million shares of Arena Pharmaceuticals exchanged hands as compared to its average daily volume of 9.4 million shares. The stock ranged in price between $8.92-$9.30 after having opened the day at $9.29 as compared to the previous trading day's close of $9.25. Other companies within the Drugs industry that declined today were:

Rexahn Pharmaceuticals



), down 32%,




), down 13.3%,




), down 10.9%, and

Supernus Pharmaceuticals



), down 10.3%.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena Pharmaceuticals has a market cap of $2.02 billion and is part of the health care sector. Shares are up 394.7% year to date as of the close of trading on Wednesday. Currently there are two analysts that rate Arena Pharmaceuticals a buy, one analyst rates it a sell, and five rate it a hold.

TheStreet Ratings rates Arena Pharmaceuticals as a


. The area that we feel has been the company's primary weakness has been its meager revenue growth.

On the positive front,

Acura Pharmaceuticals



), up 37.3%,




), up 20%,

DARA Biosciences



), up 18.6%, and

Clovis Oncology



), up 15.4%, were all gainers within the drugs industry with

Eli Lilly and Company



) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade